Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VIS 410

Next Previous
Drug Profile

VIS 410

Alternative Names: Influenza virus fusion inhibitor (VIS410) - Visterra; VIS-410

Latest Information Update: 20 May 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Visterra
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Influenza A virus infections

Most Recent Events

  • 31 Mar 2021 Discontinued - Phase-II for Influenza A virus infections (Combination therapy) in Belarus, Spain, Bulgaria, Singapore, USA, Malaysia, South Africa, Belgium, France, New Zealand, Australia, Canada, Ukraine, Estonia, Latvia, Serbia, Georgia, Thailand, Turkey, Russia (IV) before March 2021 due to company strategic reason
  • 31 Mar 2021 Discontinued - Phase-II for Influenza A virus infections in Belgium, USA, Ukraine, Latvia, Serbia, Estonia, South Africa, Bulgaria (IV) before March 2021 due to company strategic reason
  • 15 Nov 2018 Efficacy and adverse events data from a phase IIa trial in Influenza A virus infections presented at the 6th International Society for Influenza and other Respiratory Virus Diseases (ISIRV-2018)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top